TrialBMC cancer2024

Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.

Jiaxuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.